Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS

Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS
Feb 17, 2020 - By Ed Tobia


Ocrevus (ocrelizumab) bolted out of the starting gate after it was approved for use in the U.S. about three years ago. However, though its use by people with relapsing forms of Multiple Sclerosis continues to rise, fewer people with Primary Progressive MS are taking the medication. These findings from Spherix Global Insights are similar to anecdotal reports that I’ve been reading online by people who are being treated with Ocrevus.

Click HERE to Register for the MS Beacon Newsletter

First-line use of Genentech‘s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained Stable through 2019 compared to 2018, according to the latest Spherix Global Insights report.
However, the latest edition of “RealWorld Dynamix: DMT New Starts in Multiple Sclerosis (US),” based on 1,006 charts of MS patients prescribed their first disease-modifying therapy (DMT), confirms that Ocrevus prescriptions still lag behind other first-line medications, including Teva‘s Copaxone (glatiramer acetate), Biogen‘s Tecfidera (dimethyl fumarate), Mylan‘s generic glatiramer acetate, and Novartis‘ Gilenya (fingolimod).

In turn, Ocrevus use as treatment starter almost doubled among relapsing-remitting MS (RRMS) patients, while falling by half among primary progressive MS (PPMS) patients, equalling out its overall use.
Click here to read the full story.

Please subscribe to the: 
   MS Learning Channel on @YouTube

Click Red Box on banner to opt-in

This Article is Provided by:  #MSViewsandNews
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
Menopause and MS
Study uses MRI to probe non-invasively inside a li...


No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Friday, 03 April 2020

Captcha Image


Follow Us on Twitter

Follow Us On Twitter - Image